Navigation Links
Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
Date:4/16/2008

d enhance its attractiveness to potential oncology partners."

Data on Kosan's third-generation Hsp90 inhibitors were presented in two posters at the 2008 Annual Meeting of the American Association for Cancer Research (AACR), being held in San Diego, CA.

Abstract 5636, "Correlation between In Vitro and In Vivo Activities of Hsp90 Inhibitors," presented data showing the KOS-2484, Kosan's lead non-benzoquinone ansamycin, has demonstrated the tightest binding affinity for Hsp90 reported to date, accumulates in tumor cells and has superior retention properties leading to a long lifetime in tumor tissue. These properties of KOS-2484 result in this molecule showing pronounced efficacy in multiple preclinical tumor models.

Abstract 5630, "Anti-Tumor Activity of Non-Benzoquinone Ansamycin Hsp90 Inhibitors in Murine Xenograft Models," presented data showing that KOS-2484 induces tumor regression at well-tolerated doses in xenograft models of both liquid and solid tumors, including acute myelogenous leukemia (AML), multiple myeloma and colon cancer models. Most notably, KOS-2484 demonstrated almost complete regression of very large (1000 mm3) AML xenografts when dosed on an infrequent (twice a week) schedule. KOS-2484 also prolongs survival in a mouse orthotopic model of AML. These findings underscore that KOS-2484, Kosan's lead non-benzoquinone ansamycin Hsp90 inhibitor, has significant potential as a novel anticancer agent.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- a Hsp90 (heat shock protein 90) inhibitor and an epothilone. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive me
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
2. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
3. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
4. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
5. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
6. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
7. Kosan Announces February 28, 2008 Conference Call and Webcast
8. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
9. Kosan Announces Third Quarter 2007 Financial Results
10. Kosan to Reacquire Epothilone Program From Roche
11. Kosan Biosciences to Host Research & Development Day on October 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... (PRWEB) May 20, 2013 Kitware, a ... visualization tool that enables the exploration of hospital ... created in response to the recent release of “Medicare ... the top 100 most-billed procedures from the Centers for ... costs for similar procedures at hospitals across the country ...
(Date:5/20/2013)... May 20, 2013 The World Molecular ... appointment of Lisa Baird as Executive Director. Baird ... 2013. The WMIS vision is to encompass ... understand and effectively treat diseases in the developed and ... was established in 2011 by integrating the Academy of ...
(Date:5/19/2013)... MA (PRWEB) May 19, 2013 The ... social media training online, has proudly announced that the ... small business has surpassed 175,000 views on YouTube. The ... social media and SEO tips and training for small ... my students find the YouTube tips helpful for their ...
(Date:5/17/2013)... Dr. Sparano is Professor of Medicine and Professor ... Einstein College of Medicine and Associate Chairman of the ... He is also Associate Director for Clinical Research at ... Cancer Working Group, a multidisciplinary group of physicians and ... serves as Vice Chair of the National Cancer Institute ...
Breaking Biology Technology:Kitware Enables Interactive Exploration of CMS Medicare Data 2WMIS Appoints Lisa Baird as Next Executive Director 2YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3
... , SAN DIEGO, Aug. 4 Optimer Pharmaceuticals, ... the Canaccord Adams 29th Annual Global Growth Conference at the Intercontinental ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) , ... accessible on the Company,s website at www.optimerpharma.com , ...
... SOUTHAMPTON, Pa., Aug. 4 Environmental Tectonics Corporation,s ... Systems Division has been contracted with Hospimedica International Pvt. ... monoplace hyperbaric chamber. The chamber was sold through ETC,s ... Hospimedica International Pvt. Ltd. has over 20 ...
... FT. LAUDERDALE, Fla., Aug. 4 OmniComm Systems, Inc. (OTC ... (EDC) solutions for clinical trials announced today that the company ... provider, Logos Technologies, Ltd. The acquisition will be operated by ... Logos, exceptional software is used to collect clinical ...
Cached Biology Technology:Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference 2ETC Biomedical Announces Chamber Sale in India 2ETC Biomedical Announces Chamber Sale in India 3ETC Biomedical Announces Chamber Sale in India 4OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd. 2OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd. 3
(Date:5/17/2013)... the interaction of a group of proteins in the ... identified a new target that could increase cell survival. ... School of Biochemistry and published in the EMBO ... eventually lead to new therapies for stroke and other ... by the team which identified a protein, known as ...
(Date:5/17/2013)... and Sustainable Global Logistics Operations) is aiming to cut ... of intermodal loading systems and the boosting of intelligent ... organisations with experience in the logistics sector and in ... and a duration of three and a half years. ... semantic components and ontologies shared by the users, objects ...
(Date:5/17/2013)... Societies for Experimental Biology (FASEB) released a new ... trends highlighting the devastating impact of sequestration on the ... follows a May 15th Senate Appropriations Committee hearing featuring ... the $1.6 billion cut the agency sustained in FY ... on the scientific community." , According to data ...
Breaking Biology News(10 mins):SUMO wrestling cells reveal new protective mechanism target for stroke 2New logistics services that will cut energy consumption and CO2 emissions 2
... obesity scale in a new international study of adolescents ... professor in Queen's University's School of Physical & Health ... And sedentary behaviour ?like watching television ?was strongly correlated ... alarming finding is one that runs contrary to what ...
... day benefit from treatment with mixtures of customized antibodies. ... the National Academy of Sciences (USA), a team of ... might form a web that destroys the cancer cell's ... of intensive cancer research led to the identification of ...
... Earth roughly every 26 million years, leading some scientists ... collisions with comets or asteroids. A researcher in Poland ... at fault instead. , Adam Lipowski (Adam Mickiewicz University) ... both food and living space. The model also included ...
Cached Biology News:Canadian youth 4th highest in international obesity study 2Two are better than one 2
... The BV-10 offers precision ... 0.1 and 50m. The unique ... vibration free for greater control ... can be accomplished very rapidly ...
...
... Lyophilized. Lyophilized from 2 mM ... from human liver. Cathepsin D is a ... produced as a 52 kDa proenzyme. Overexpression ... is associated with higher risk of relapse ...
... highly purified preparation qualified to specifically cleave ... preparation is functionally tested for activity with ... contaminating proteases. Prepared from human plasma that ... be negative for HBsAg and for antibodies ...
Biology Products: